The perception of dyspnoea differs between subjects with obstructive pulmonary diseases, partly because the underlying mechanisms for bronchoconstriction are different. We investigated the perception of bronchoconstriction in subjects with bronchiectasis, asthma and chronic bronchitis and possible contributing factors. Forty-seven non-smoking subjects with bronchiectasis, 50 subjects with asthma and 31 with chronic bronchitis were challenged with histamine. The Borg score was assessed before and after each challenge. The perception score corresponding to a fall in the forced expiratory volume in 1 s (FEV 1 ) by 20 % (PS 20 ) was calculated. The mean values of Borg/ FEV 1 (the Borg score change divided by the change in FEV 1 as a percentage of the baseline FEV 1 ) and PS 20 of subjects with bronchiectasis and chronic bronchitis were significantly lower than in subjects with asthma after histamine challenge. The ratio of non-perceivers was higher in bronchiectasis (25.5 %) and in chronic bronchitis (32.3 %) than in asthma (4.0 %). When all subjects were considered, Borg / FEV 1 values were significantly related to female sex (r 2 = 11.5 %, P = 0.0001), but not to age, duration of the disease, PD 20 or baseline FEV 1 %. The present study indicates that perception of histamine-induced bronchoconstriction is lower in patients with bronchiectasis and chronic bronchitis than in asthmatic patients, and that sex partially contributes to this difference.
INTRODUCTION
Perception of bronchoconstriction varies between individuals [1] . Although the sensory structures are common to all diseases, the conditions of stimulation may be different in the different disorders. The difference may be related to the type of constricted airway, the rapidity and duration of constriction, or characteristics of inflammatory components in airways [2] . Moreover, the range and duration of the stimulus and the state of to clearly identify the mechanisms responsible for the differences in perception of dyspnoea in airway diseases [5] . It may be hypothesized that perception of dyspnoea may be different among subjects with bronchiectasis, asthma and chronic bronchitis, because the underlying mechanisms for bronchoconstriction are different.
To investigate the differences in dyspnoea sensation among patients with bronchiectasis, asthma and chronic bronchitis, the Borg scores were measured before and after histamine challenge. Moreover, the contribution of clinical variables to changes in perceived bronchoconstriction was assessed.
METHODS

Study group
We studied 128 consecutive patients, 47 with bronchiectasis, 50 with asthma and 31 with chronic bronchitis. All patients signed informed consent forms, and the study was approved by the Local Ethics Committee. Diagnosis of asthma and chronic bronchitis were done according to the American Thoracic Society criteria [6] . Detailed history, physical examination and spirometric measurements were obtained from each patient. Patients with chronic bronchitis were current smokers (mean packyears = 33.67 + − 20.43, range 8-96). All the patients with bronchiectasis and asthma were non-smokers. Atopy was determined by skin-prick tests to common inhalant allergens (Center Laboratories, Port Washington, NY, U.S.A.). The following were taken as exclusion criteria: cardiac disorder, cognitive impairment, treatment with systemic corticosteroids and respiratory tract infection in the previous 4 weeks.
Thin-section computerized tomography (CT) scans of patients with bronchiectasis were obtained at endinspiration and reinterpreted by a chest physician and a radiologist. The CT diagnosis of bronchiectasis was established according to adopted criteria [7, 8] . Central bronchi, which were greater in diameter than the adjacent vessels and bronchi depicted in the peripheral third of the lung field in thin-section CT, were considered as bronchiectasis.
Histamine challenge test
Patients were asked to stop using bronchodilating agents for at least 12 h before the histamine challenge test. Pulmonary functions were measured by a flow-sensing spirometer connected to a computer for data analysis (Jaeger, Wuerzburg, Germany) [9] . Each subject inhaled doubling concentrations of histamine up to 16 mg/ml or until a 20 % decrease in forced expiratory volume in 1 s (FEV 1 ), via a dosimeter with an output of 9 + − 0.3 ml/puff (Dosimeter APS Pro; Jaeger, Wuerzburg, Germany). Bronchial response to histamine was expressed as the provocative dose causing a 20 % decrease in FEV 1 (PD 20 , in mg/ml) and was calculated by the same computer program (LAB, version 4.3; Jaeger). PD 20 was expressed as the geometric mean + − SD.
Perception of bronchoconstriction
Perceived intensity of dyspnoea was estimated using a modified Borg scale labelled from 0 (no symptom) to 10 (maximum bearable) [10] . Patients were asked to select an appropriate definition to determine dyspnoea at the time of the test. They were completely free to decide their own self-scores, but warned to determine only dyspnoea and to disregard any irritation of the nose or throat during the scoring. Borg scores were recorded immediately before each percentage of the predicted value for FEV 1 (FEV 1 %) measurement during the challenge test and at the maximum fall of FEV 1 %. The perception score corresponding to a fall in FEV 1 by 20 % (PS 20 ) was calculated by linear interpolation of the last two points on the perception/fall in the FEV 1 % curve of the histamine challenge test [11] . The change in dyspnoea during bronchoconstriction was expressed as the Borg score change divided by the change in FEV 1 as a percentage of the baseline FEV 1 ( Borg/ FEV 1 ) [12] .
Statistical analysis
Clinical data were expressed as the geometric mean + − S.D. Differences between three groups were assessed using multivariate analysis of variance and Student's t test. Multiple linear regression analysis was performed with the perception of bronchoconstriction ( Borg/ FEV 1 or PS 20 ) as the dependent variable and the baseline FEV 1 %, PD 20 , sex, age, duration of disease and cigarette pack-year as predictor variables. Predictor variables were entered in the multivariate model using a stepwise procedure. Differences in the distribution of nonperceivers ( Borg = 0) between groups were analysed using the χ 2 test. All tests were performed two-sided, and P < 0.05 was considered to be significant.
RESULTS
Demographic characteristics and spirometric data of patient groups are presented in Table 1 . Subjects with bronchiectasis showed significantly lower baseline FEV 1 % values than the asthmatic patients (P = 0.003). There were relatively more male subjects among patients with chronic bronchitis than in asthmatics (93.5 % and 18.0 %; P = 0.0001).
Twelve out of 47 subjects with bronchiectasis, 10 with chronic bronchitis and 2 out of 50 asthmatics did not indicate any increase in sensation of dyspnoea (Borg score) with induced bronchoconstriction (25.5 %, 32.3 % and 4.0 % respectively). The mean values of Borg/ FEV 1 and PS 20 in subjects with bronchiectasis and chronic bronchitis were significantly lower than in subjects with asthma after histamine challenge (P < 0.05) (Figure 1 ). Neither Borg/ FEV 1 nor PS 20 differed between bronchiectasis and chronic bronchitis groups. Individual changes in Borg during histamine challenge in three groups of patients are shown in Figure 2 .
When all subjects were considered, female subjects had significantly higher Borg/ FEV 1 and PS 20 than males (0.098 + − 0.062 compared with 0.056 + − 0.052, and 1.94 + − 1.21 compared with 1.12 + − 1.04 respectively; P = 0.0001). Consequently, female sex was the only variable correlated with Borg/ FEV 1 values in bronchiectasis (r 2 = 12.0 %, P = 0.01) and in chronic bronchitis group (r 2 = 22.6 %, P = 0.01), as well as in overall subjects (r 2 = 11.5 %, P = 0.0001). Similar results were obtained when PS 20 was considered as the perception of dyspnoea. When assessing the bronchiectasis group with the asthma group, Borg/ FEV 1 was related to female sex (r 2 = 8.2 %, P = 0.004), but not to age,
Figure 2 Relationship between Borg and FEV 1 in patient groups
Results for bronchiectasis (ᮀ), asthma (᭞) and chronic bronchitis ( * ) patient groups are shown. Regression lines for bronchiectasis (broken line), asthma (solid line) and chronic bronchitis (dotted line) patient groups are also shown.
duration of the disease, PD 20 or baseline FEV 1 %. Similarly, the relationship between Borg/ FEV 1 and females was significant (r 2 = 13.9 %, P = 0.001) in chronic bronchitis group compared with asthmatics.
DISCUSSION
This study demonstrates that the perception of histamineinduced bronchoconstriction was poorer in patients with bronchiectasis and chronic bronchitis than in asthmatic subjects.
The reasons for the difference in the perception of dyspnoea among these groups are unknown. However, the discrepancies in the natural course of these three diseases could account for differences in dyspnoea sensation. It is known that asthmatic patients experience episodic bronchoconstriction, whereas those with chronic bronchitis and bronchiectasis have persistent bronchoconstriction and the chronicity of this symptom may lead to desensitization [12] . The obstructive defect associated with obliterative bronchiolitis, collapse of large airways on expiration, retention of endobronchial secretions, emphysema and airway hyper-responsiveness that is partially different from chronic bronchitis or asthma may play a role in poor perception of dyspnoea in bronchiectasis [13] . The differences in bronchial hyperresponsiveness (BHR) and in airway wall inflammation may be important for the difference in the severity of induced bronchoconstriction. BHR in asthma may result from lymphocytic inflammation and secretion of cytokines from Th2 lymphocytes [14] , whereas in chronic bronchitis it is due to increased airway smooth muscle mass, loss of elastic recoil, airway inflammation and decreased airway diameter [12] . Damage to sensory nerves, as a result of prolonged bronchial suppuration or by increased access to toxins through infected or inflamed bronchial mucosa in bronchiectasis, not only causes BHR, but also plays a partial role in low perception [15] .
Rutgers et al. [12] have shown that the perception of dyspnoea is lower in chronic obstructive pulmonary disease (COPD) than in asthma. In another study [16] , it was reported that the smokers with airflow limitation had lower perception of methacholine-induced bronchoconstriction. Although several studies have compared the perception of dyspnoea between asthma and COPD [17] [18] [19] [20] , none indicated bronchiectasis. To our knowledge, the present study is the first study investigating the perception of bronchoconstriction in patients with bronchiectasis. Our results showed some similarities with the previous studies performed in patients with COPD and with asthma. Conversely, Ward and Stubbing [21] have shown that the perception of added resistive loads to breathing in chronic airway limitation and the perception of added elastic loads in chronic interstitial lung diseases are not different from normal subjects. However, comparisons between studies are difficult due to differences in disease severity, distribution of age and sex, the methods assessing dyspnoea or cultural characteristics of each particular community.
Some studies dealing with the relationship between dyspnoea and bronchodilation have described 'perceivers' and 'non-perceivers' after administration of a bronchodilator agent [19] . In the present study, a quarter of the subjects with bronchiectasis did not indicate an increase in Borg at all after histamine challenge, whereas one-third of patients with chronic bronchitis were nonperceivers. This group of patients should be followed closely, because early recognition and treatment of acute exacerbation could be delayed, causing an increase in the morbidity and mortality.
Killian et al. [22] showed that females were 13 % more dyspnoeic than males after a 20 % decrease in FEV 1 during methacholine-induced bronchoconstriction in asthmatics. Likewise, identical magnitude of breathlessness was observed both in symptomatic obstructive airway disease and age/sex-matched control subjects. A similar distribution in this study may suggest the effect of sex on perception of dyspnoea. Our present data seem to support the findings that the perceived bronchoconstriction is related to sex.
In the present study, it was found that females reported a greater sensation of dyspnoea than males in all groups, as has been shown in other studies [23] [24] [25] . In contrast, Noseda et al. [18] neglected the effect of sex on low perception in COPD, whereas others found no difference between the sexes in asthmatic subjects [26, 27] . In a more recent study [12] , sex was not important in explaining the variance in perception of bronchoconstriction, although there were relatively more male subjects in the COPD group. Despite the fact that the possible effect of sex distribution on differences of dyspnoea perception in different diseases has not been assessed thoroughly, we suggest that male predominance may play a partial role in poor perception in chronic bronchitis after multivariate analysis.
We also found that the perceptual characteristics ( Borg/ FEV 1 and PS 20 values) were unrelated to baseline airway function (FEV 1 %) in obstructive lung diseases, as observed in other studies [20, [28] [29] [30] . It was suggested that subjects with resting obstruction develop temporal adaptation to poor lung function [31] . Borg/ FEV 1 and PS 20 values were not related to cigarette pack-year in chronic bronchitis. Consistent with our present results, Ottanelli et al. [30] showed that patients with airflow limitation may variably perceive bronchoconstriction independent of smoking history. In contrast, it has been postulated that prolonged exposure to cigarette smoke may lead to chronic depletion of sensory nerve neurotransmitters and abnormalities in sensory nerves might diminish the perception of bronchoconstriction in smokers [16, 17] .
In conclusion, acute decrease in airway caliber is perceived less in patients with chronic bronchitis and bronchiectasis than in asthmatics. It is not possible to estimate the underlying mechanisms responsible for the differences, because the aim of this study was to look at perception of bronchoconstriction in three groups of patients with bronchiectasis, asthma and chronic bronchitis. Whether the perception of dyspnoea during histamine-induced bronchoconstriction in bronchiectasis differs from that spontaneously occurring in chronic bronchitis remains to be determined in future studies. As the conclusive results of studies with various groups will be reproduced, mechanisms of disease-specific differences in perception of dyspnoea will be identified.
